Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Common Equity (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Common Equity for 16 consecutive years, with $142.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 44.59% to $142.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $142.3 million through Dec 2025, up 44.59% year-over-year, with the annual reading at $142.3 million for FY2025, 44.59% up from the prior year.
  • Common Equity for Q4 2025 was $142.3 million at Gyre Therapeutics, up from $101.9 million in the prior quarter.
  • The five-year high for Common Equity was $142.3 million in Q4 2025, with the low at $13.9 million in Q4 2023.
  • Average Common Equity over 5 years is $81.4 million, with a median of $85.2 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 80.68% in 2023, then soared 605.44% in 2024.
  • Over 5 years, Common Equity stood at $59.5 million in 2021, then grew by 21.44% to $72.2 million in 2022, then crashed by 80.68% to $13.9 million in 2023, then skyrocketed by 605.44% to $98.4 million in 2024, then surged by 44.59% to $142.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $142.3 million, $101.9 million, and $129.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.